Yue Cheng

Yue Cheng

Auto-generated profile, based on publicly available information

Yue Cheng

West China Hospital of Sichuan University

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
YCYan Chen
Yan Chen
YXYanguo Xin
Yanguo Xin
YCYue Cheng
Yue Cheng
XLXiaojing Liu
Xiaojing Liu
Diabetic cardiomyopathy (DCM), as a serious complication of diabetes, causes structural and functional abnormalities of the heart and eventually progresses to heart failure. Currently, there is no specific treatment for DCM. Studies have proved that mitochondrial dysfunction and endoplasmic reticulum (ER) stress are key factors for the development and progression of DCM. The mitochondria‐associated ER membranes (MAMs) are a unique domain formed by physical contacts between mitochondria and ER and mediate organelle communication. Under high glucose conditions, changes in the distance and composition of MAMs lead to abnormal intracellular signal transduction, which will affect the physiological function of MAMs, such as alter the Ca2+ homeostasis in cardiomyocytes, and lead to mitochondrial dysfunction and abnormal apoptosis. Therefore, the dysfunction of MAMs is closely related to the pathogenesis of DCM. In this review, we summarized the evidence for the role of MAMs in DCM and described that MAMs participated directly or indirectly in the regulation of the pathophysiological process of DCM via the regulation of Ca2+ signaling, mitochondrial dynamics, ER stress, autophagy, and inflammation. Finally, we discussed the clinical transformation prospects and technical limitations of MAMs‐associated proteins (such as MFN2, FUNDC1, and GSK3β) as potential therapeutic targets for DCM.

18 February 2020 in Biomedical Optics Express
Verified
Journal Article
Closed access
PRPanpan Rao
Panpan Rao
LWLong Wang
Long Wang
YCYue Cheng
Yue Cheng
XWXi Wang
Xi Wang
HLHaitao Li
Haitao Li
CHCongxin Huang
Congxin Huang
This study determines whether near-infrared (NIR) light can drive tissue-penetrating cardiac optical control with upconversion luminescent materials. Adeno-associated virus (AAV) encoding channelrhodopsin-2 (ChR2) was injected intravenously to rats to achieve ChR2 expression in the heart. The upconversion nanoparticles (UCNP) NaYF4:Yb/Tm or upconversion microparticles (UCMP) NaYF4 to upconvert blue light were selected to fabricate freestanding polydimethylsiloxane films. These were attached on the ventricle and covered with muscle tissue. Additionally, a 980-nm NIR laser was programmed and illuminated on the film or the tissue. The NIR laser successfully captured ectopic paced rhythm in the heart, which displays similar manipulation characteristics to those triggered by blue light. Our results highlight the feasibility of tissue-penetration cardiac optogenetics by NIR and demonstrate the potential to use external optical manipulation for non-invasive or weakly invasive applications in cardiovascular diseases.

29 January 2021 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
YCYue Cheng
Yue Cheng
YXYao Xie
Yao Xie
YCYan Chen
Yan Chen
XLXiaojing Liu
Xiaojing Liu
Currently, traditional cancer therapy still falls far short of expectations. However, a variety of invasive cancers that are resistant to chemotherapy (such as platinum drugs, one of the most applied antineoplastics in clinic) and targeted agents are susceptible to ferroptosis. Ferroptosis is a form of cell death that is driven by cell metabolism and iron‐dependent lipid peroxidation. Ferroptosis inducers can eliminate the drug resistance of tumor cells in the mesenchymal state, effectively inhibit the drug resistance of acquired tumor cells, and optimize cancer efficacy. Research based on the epigenetic mechanism of ferroptosis is still in the stage of screening and verifying the regulatory effect, and there is no complete regulatory mechanism network. In this review, we expound on the epigenetic regulation and nonepigenetic mechanisms of ferroptosis and review the epigenetic‐based mechanisms of tumor therapy potential and emerging nonepigenetic‐based therapies (nanotherapeutics).

1 June 2019 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Open access
YCYue Cheng
Yue Cheng
HLHaitao Li
Haitao Li
HLHong Lei
Hong Lei
CJChan Jiang
Chan Jiang
PRPanpan Rao
Panpan Rao
XWXi Wang
Xi Wang
Optogenetics is an innovative method for precise control of biological function, which makes light manipulation displays more advantages than electric energy because of contactless spatial flexibility and cell-to-cell synchronous communication. The aim of this study was to perform different illumination modes with blue laser to investigate optical control of the mice hearts. In this study, we transfected the light sensitive protein ChR2(H134R) into mouse hearts, which were illuminated with a 473 nm laser on the Langendorff apparatus. We recorded all the signals of electrograms (EGs), epicardium monophasic action potential (MAPs) and light output signals to analyze myocardial electrical activity. EGs and MAP showed that ChR2 expression in the heart can be flexibly controlled by blue light across different illumination sites with corresponding triggered ectopic rhythm. Illumination intensity, pulse duration, and impulse frequency were associated with the light capture rate. Continuous illumination with the threshold intensity on the left ventricle had little influence on sinus rhythm and ventricular electrophysiology. Our results support that flexible control of the cardiac rhythm with optogenetics provides an innovative approach to cardiac research and therapy.

2 December 2025 in Expert Opinion on Investigational Drugs
Verified
Journal Article
Closed access
YCYue Cheng
Yue Cheng
XZXiaohong Zhu
Xiaohong Zhu
ZLZhihui Liu
Zhihui Liu
YWYing Wang
Ying Wang
YMYuchun Men
Yuchun Men
PFPing Feng
Ping Feng
KL130008, a novel selective JAK1/JAK2 inhibitor demonstrated acceptable safety and tolerability in Phase I studies involving healthy volunteers. This proof-of-concept trial aimed to characterize the pharmacokinetic/pharmacodynamics relationship and preliminary efficacy of KL130008 in rheumatoid arthritis (RA) patients. In this randomized, double-blind, single-center trial involving 30 RA patients, 24 received oral KL130008 and 6 received placebo. Pharmacokinetics and pharmacodynamics were evaluated based on drug concentrations and on inhibition of phospho-signal transducer and activator of transcription-3 (pSTAT3). Safety and efficacy outcomes were assessed. Pharmacokinetics were linear over the dose from 1-4 mg; the drug showed the half-life of 14.34-18.14 h and accumulation factor of 1.27-1.76. The drug inhibited pSTAT3 with a dose-dependent trend, achieving maximal inhibition of 37.61% (1 mg), 61.28% (2 mg), and 71.87% (4 mg). The American College of Rheumatology 20 responses (≥20% improvement from baseline) were 25.0-37.5% across the dose range of 1-4 mg after two weeks of multiple dosing, higher than 16.7% for placebo. Treatment-emergent adverse events, all mild, occurred in two-thirds of patients receiving KL130008. In RA patients, oral KL130008 shows linear pharmacokinetics, pSTAT3 inhibition, and promising safety. Efficacy are exploratory given the small sample size. Registered in the Chinese Clinical Trial Register (ChiCTR2000029360).

3 October 2025 in Expert Opinion on Drug Metabolism & Toxicology
Verified
Journal Article
Closed access
YCYue Cheng
Yue Cheng
MCMan Chen
Man Chen
JYJing Yu
Jing Yu
HGHuiping Gong
Huiping Gong
ZXZunfang Xu
Zunfang Xu
PFPing Feng
Ping Feng
The combination of the JAK1/2 inhibitor KL130008 with methotrexate (MTX) is expected to improve treatment outcomes in rheumatoid arthritis (RA). This study evaluated the pharmacokinetics and safety of this combination therapy. In an open-label, multicenter trial, 31 patients with RA received KL130008 combined with MTX. Pharmacokinetic parameters (Cmax, AUC0-t, AUC0-∞, Tmax) were assessed and compared between combination and monotherapy. Safety was evaluated through treatment-emergent adverse events (TEAEs), laboratory tests, and ECGs. Primary endpoints were pharmacokinetic bioequivalence between combination and monotherapy. Secondary outcomes included safety and tolerability. Geometric mean ratios and 90% confidence intervals for key pharmacokinetic parameters of KL130008 and MTX were within the 80-125% bioequivalence range, indicating no significant interaction. A slight increase in 7-OH-methotrexate exposure was observed but deemed clinically insignificant. TEAEs related to KL130008 occurred in 71.0% of patients, with anemia (25.8%) and increased platelet count (12.9%) most common. All abnormal laboratory or ECG findings were mild. KL130008 combined with MTX demonstrated favorable pharmacokinetics and acceptable safety in RA patients. These findings support further investigation of this combination. Limitations include the open-label design and small sample size. This trial was registered with the Chinese Clinical Trial Register (ChiCTR2100050764) on 4 September 2021.